177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Published Online: 2021-12-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Amy Bartalotta•Andrew Hendifar•Arnaud Demange•Edward M Wolin•Enrique Grande•Eric P Krenning•Eric Van Cutsem•Erik Mittra•Ettore Seregni•Germo Gericke•Hugo Duarte•James C Yao•Jonathan R Strosberg•Lisa Bodei•Marianne E Pavel•Martyn E Caplin•Maurizio F Mariani•Pamela L Kunz•Philippe B Ruszniewski•Sakir Mutevelic
